Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2016

View Archived Issues

AstraZeneca reflects on highlights of fourth quarter 2015

City of Hope develops technology to create cell-permeable antibodies

OncoMed gives update on ALPINE and PINNACLE studies of tarextumab

PharmaMar's phase III lurbinectedin study to continue

Aurinia Pharmaceuticals completes preliminary analysis of AURION study

Innov17 patents retinoid-related orphan receptor ligands

Cisen Pharmaceutical and Medshine Discovery reveal compounds to treat tuberculosis

FDA places full clinical hold on pacritinib

New animal model created for the investigation of glanders

PDS Biotechnology and NCI to codevelop novel cancer immunotherapies

Adaptimmune's NY-ESO T-cell therapy earns FDA breakthrough therapy designation

Sanofi presents milestones of fourth quarter 2015

Study of amifampridine phosphate in MuSK-antibody positive myasthenia gravis begins

Novel fibrinogen mutations are associated with congenital hypofibrinogenemia

VBI and GSK enter vaccine research collaboration

Phase I data support progression of Immune Design's immuno-oncology candidates

Cellceutix plans SPA request for phase III study of brilacidin in ABSSSI

Target for interfering with MYC oncogene activity identified

Merck & Co. files BLA for house dust mite SLIT tablet

Scientists identify unusual mutations in moderate hemophilia B patients

FDA recommends approval of Celltrion's infliximab biosimilar, Epirus advances own biosimilar

BioCryst reports phase II/III results for liquid capsule formulation of avoralstat

Nymox announces results from phase II prostate cancer study

EMA creates Zika virus task force, HemispheRx announces its approach

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...